Fig. 2.

Patient attrition. ^aIncluding patients with mild, moderate, and severe baseline SLE. Patients with mild SLE, as well as 2160 patients with the use of ≥ 2 IS during the baseline period, were excluded from this analysis. IS immunosuppressant, JAK Janus kinase inhibitor, SLE systemic lupus erythematosus